Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BLESSY M JACOB

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1851525406
CMS profile
1379799
Location
ENGLEWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,563.74

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BLESSY M JACOB

NPI 1851525406 · CMS profile ID 1379799

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ENGLEWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851525406?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BLESSY M JACOB, NPI 1851525406, CMS profile ID 1379799. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851525406?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BLESSY M JACOB, NPI 1851525406, CMS profile ID 1379799. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851525406?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BLESSY M JACOB, NPI 1851525406, CMS profile ID 1379799, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1851525406?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $2,563.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $70.1307/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136082384 CMS
Acrotech Biopharma Inc. $14.2207/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147105259 CMS
Genmab U.S., Inc. $26.8607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126824809 CMS
Lilly USA, LLC $22.3907/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136069902 CMS
PFIZER INC. $23.2807/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131344194 CMS
ARRAY BIOPHARMA INC $17.4607/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131338283 CMS
Alexion Pharmaceuticals, Inc. $27.7907/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093933863 CMS
Janssen Biotech, Inc. $16.1407/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078414619 CMS
AstraZeneca Pharmaceuticals LP $14.4206/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105640550 CMS
Astellas Pharma US Inc $25.6406/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139370783 CMS
Lilly USA, LLC $14.5306/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136066221 CMS
PFIZER INC. $19.7406/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131328760 CMS
Novartis Pharmaceuticals Corporation $17.4306/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087098070 CMS
PFIZER INC. $26.8106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131328752 CMS
Sumitomo Pharma America, Inc. $17.6306/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148868411 CMS
Mirati Therapeutics, Inc. $24.1606/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117161600 CMS
PFIZER INC. $11.9606/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131328756 CMS
E.R. Squibb & Sons, L.L.C. $17.4606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249173 CMS
Daiichi Sankyo Inc. $29.8306/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089436955 CMS
SOBI, INC $14.3906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141424851 CMS
PFIZER INC. $26.5806/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131547983 CMS
Janssen Biotech, Inc. $25.6506/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078414671 CMS
Astellas Pharma US Inc $14.2005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139349548 CMS
Lilly USA, LLC $18.9605/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136016225 CMS
Incyte Corporation $29.2205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141259389 CMS
Acrotech Biopharma Inc. $125.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147105257 CMS
Lilly USA, LLC $17.4405/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136082388 CMS
Astellas Pharma US Inc $23.4305/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139333568 CMS
Novartis Pharmaceuticals Corporation $15.0505/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087098066 CMS
Merck Sharp & Dohme LLC $29.4105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141961524 CMS
TAIHO ONCOLOGY, INC. $16.5704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137945603 CMS
Fennec Pharmaceuticals, Inc. $23.4404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120186806 CMS
E.R. Squibb & Sons, L.L.C. $18.1004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101249161 CMS
PFIZER INC. $13.3304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131297802 CMS
Novartis Pharmaceuticals Corporation $14.0804/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087098054 CMS
Rigel Pharmaceuticals, Inc. $25.9104/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145202562 CMS
AstraZeneca Pharmaceuticals LP $24.6004/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104259969 CMS
AstraZeneca Pharmaceuticals LP $27.0103/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105830353 CMS
Astellas Pharma US Inc $24.3003/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139330210 CMS
Exelixis Inc. $17.2303/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138555981 CMS
Genentech USA, Inc. $15.0903/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132981793 CMS
PFIZER INC. $13.2203/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294028 CMS
PFIZER INC. $19.0803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131277680 CMS
Novartis Pharmaceuticals Corporation $14.8503/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087098062 CMS
Regeneron Healthcare Solutions, Inc. $15.2103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114075754 CMS
Novartis Pharmaceuticals Corporation $20.9802/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087098046 CMS
GENZYME CORPORATION $14.5902/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828074 CMS
Eisai Inc. $22.8702/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110733773 CMS
AstraZeneca Pharmaceuticals LP $24.9902/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105682941 CMS
Janssen Biotech, Inc. $17.0602/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078414567 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,885.39 126
PY2020 $556.66 35
PY2021 $2,029.60 41
PY2022 $1,938.02 101
PY2023 $2,366.39 112
PY2024 $2,563.74 116
PY2025 $3,357.24 147

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $556,367.84 31
PY2024 Principal investigator $444,550.32 12
PY2023 Principal investigator $217,162.01 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,166.00 12/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235993903
Principal investigator 1 PFIZER INC. $273.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228737123
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,338.89 10/28/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190307051
Principal investigator 1 PFIZER INC. $3,703.80 10/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228741664
Principal investigator 1 PFIZER INC. $1,294.80 09/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228758776
Principal investigator 1 ABBVIE INC. $3,913.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504895
Principal investigator 1 ABBVIE INC. $7,007.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504897
Principal investigator 1 PFIZER INC. $3,990.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228768358
Principal investigator 1 Celgene Corporation $51,693.33 07/25/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222305578
Principal investigator 1 ABBVIE INC. $200.00 07/24/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202499656
Principal investigator 1 PFIZER INC. $1,556.40 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228788919
Principal investigator 1 PFIZER INC. $4,540.00 05/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228783435
Principal investigator 1 Celgene Corporation $11,666.00 05/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222306723
Principal investigator 1 PFIZER INC. $637.00 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228773220
Principal investigator 1 PFIZER INC. $1,228.00 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228789180
Principal investigator 1 ABBVIE INC. $3,185.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464024
Principal investigator 1 ABBVIE INC. $3,640.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464028
Principal investigator 1 ABBVIE INC. $819.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464033
Principal investigator 1 ABBVIE INC. $4,186.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464143
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464146
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464150
Principal investigator 1 ABBVIE INC. $4,186.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464157
Principal investigator 1 ABBVIE INC. $1,729.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464161
Principal investigator 1 ABBVIE INC. $2,275.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464166
Principal investigator 1 ABBVIE INC. $7,007.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463271
Principal investigator 1 ABBVIE INC. $1,820.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463278
Principal investigator 1 ABBVIE INC. $8,281.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463360
Principal investigator 1 ABBVIE INC. $11,921.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463363
Principal investigator 1 ABBVIE INC. $2,002.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463625
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $617.59 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialists - South
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235997331
Principal investigator 1 Novartis Pharmaceuticals Corporation $393,306.03 01/01/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190307053